It is made available under a CC-BY 4.0 International license .

- 1 Title Page
- 2
- 3 Title:
- 4 The international trial of nasal oxygen therapy after cardiac surgery (NOTACS) in patients at high risk of
- 5 postoperative pulmonary complications: Economic evaluation protocol and analysis plan
- 6
- 7 Short title:
- 8 Economic evaluation protocol for NOTACS trial
- 9
- 10 Authors and affiliations:
- 11 Siddesh Shetty¹, Melissa Duckworth², Richard Norman³, Jacquita Affandi^{3,4}, Sarah Dawson^{2,5}, Julia Fox-
- 12 Rushby^{1, *}, On behalf of NOTACS investigators⁶, On behalf of NOTACS Trial Steering Committee⁶, On
- 13 behalf of NOTACS DMEC Committee⁶

14

- ¹ School of Life Course and Population Sciences, King's College London, United Kingdom
- ² Papworth Trials Unit Collaboration, Royal Papworth Hospital NHS Foundation Trust, Cambridge, United
- 17 Kingdom
- 18 ³ Curtin School of Population Health, Curtin University, Perth, Western Australia
- 19 ⁴ Fiona Stanley Hospital, Perth, Western Australia
- ⁵ MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom

It is made available under a CC-BY 4.0 International license .

- ⁶ Membership of the NOTACS investigators, NOTACS Trial Steering Committee and NOTACS DMEC
- 22 Committee is provided in the supplementary S2 appendix
- 23 * Corresponding author
- 24 E-mail: julia.fox-rushby@kcl.ac.uk (JF)
- 25

26 Abstract:

27

28 Introduction

High-Flow Nasal Therapy (HFNT) is an innovative non-invasive form of respiratory support. Compared to standard oxygen therapy (SOT), there is an equipoise regarding the effect of HFNT on patient-centred outcomes among those at high risk of developing postoperative pulmonary complications after undergoing cardiac surgery. The NOTACS trial aims to determine the clinical and cost-effectiveness of HFNT compared to SOT within 90 days of surgery in the United Kingdom, Australia, and New Zealand. This protocol describes the methods and analyses planned for economic evaluation embedded within the ongoing NOTACS trial.

36

37 Methods and analysis

The economic evaluation will identify, measure and value resources and health outcomes in both trial arms and compare changes in costs with 'days alive and at home' and EQ-5D-5L quality adjusted life years (QALYs) from the perspective most relevant to the decision-making country. Results from pooling data across the trial will use health and social care sector perspective. All patient-specific data including

42	hospital/community care and health outcomes will be collected prospectively. Unit costs will be sourced
43	from national, published or local data. Missing data will be assessed, with values replaced depending on
44	assumed mechanism of missingness, and impact of replacement on cost-effectiveness assessed. Costs and
45	outcomes by trial arm will be presented as components and totals per patient using a range of descriptive
46	statistics. Regression models for costs and effects will account for patient characteristics, quality of life
47	and health service utilization at baseline. Uncertainty in parameters, sampling and heterogeneity will be
48	addressed through deterministic, probabilistic and subgroup analyses to assess the impact of varying
49	methods and assumptions for costs, outcomes and approaches used in base-case analysis. Results will be
50	interpreted using recommended national cost-effectiveness thresholds.
51	
52	Registration details
53	The study is registered with ISRCTN (ISRCTN14092678) on 13/05/2020. ISRCTN is a primary registry of
54	the WHO ICTRP network and includes all items from the WHO Trial Registration data set.
55	
56	
57	
58	
59	
60	
61	
62	

It is made available under a CC-BY 4.0 International license .

63 Introduction:

United Kingdom (UK), Australia (AUS), and New Zealand (NZ) reported a total of 42,456 cardiac surgical procedures in 2022-23 (1,2). Patients undergoing cardiac surgery are at risk of developing postoperative pulmonary complications (PPC), leading to prolonged hospitalisation and an increase in healthcare costs (3,4). The risk is further exacerbated in patients having intrinsic respiratory disease and lower airway obstruction, obese patients, and heavy smokers (5). The peri-extubation period is crucial in managing such high-risk patients. These patients more often require prolonged ventilatory support and readmission during recovery (6,7).

71

72 High-Flow Nasal Therapy (HFNT) is an innovative non-invasive form of respiratory support that has 73 increasingly gained attention as a bridge between low flow oxygen and continuous positive airway 74 pressure (CPAP) (8). HFNT has physiological benefits and is better tolerated by patients compared to other 75 techniques of non-invasive ventilation (NIV) and conventional oxygen therapy (9). Recent systematic 76 reviews have ascertained the efficacy and safety of HFNT in adult post-operative patients by 77 demonstrating a reduction in length of hospital stay and the need for respiratory support (10,11). There is however an equipoise regarding the use of HFNT in patients at high risk of developing PPC undergoing 78 79 cardiac surgery.

80

The NOTACS trial is an adaptive, multi-centre, multi-country, parallel group, randomised controlled trial (RCT) with embedded economic evaluation. The trial compares the use of HFNT versus SOT in patients at high risk of developing PPC after undergoing cardiac surgery. The trial has two primary aims; to determine whether prophylactic use of HFNT for a minimum of 16 hours after tracheal extubation increases days

It is made available under a CC-BY 4.0 International license .

alive and at home (DAH) at 90 days after surgery, and to estimate the incremental cost-effectiveness and
 cost-utility of HFNT versus SOT at 90 days after surgery.

87

88 There is very little evidence available on the cost-effectiveness of HFNT. A decision model from England 89 found HFNT to be cost saving in ICU patients but indicated limitations with clinical effectiveness and 90 costing methods (12). Similarly, a US-based model found HFNT to be cost-effective in COPD patients on long-term oxygen but is based on findings from a single-centre trial that used outcomes from a different 91 92 healthcare setting (13). The limited available economic evidence is mostly based on decision models. 93 heterogenous population subgroups, different settings that have limitations for input costs, consequences 94 or are funded by manufacturers (12–16). Therefore, the actual cost-effectiveness of HFNT in adult patients 95 at high risk of developing PPC undergoing cardiac surgery is currently unknown.

96

The economic evaluation alongside NOTACS is designed to provide the first international economic 97 98 evidence on the use of HFNT for adults at high risk of developing PPC undergoing cardiac surgery. The 99 primary objective is to assess the cost-effectiveness (i.e. incremental cost per gain in 'days alive and at 100 home' at 90 days after surgery (DAH90)) and cost-utility (i.e. incremental cost per Quality Adjusted Life 101 Years (QALY) gained) for HFNT versus SOT comparison from the health and social care sector perspective. 102 The secondary objectives include addition of patient/family perspective and estimation of costeffectiveness at 30 days after surgery. This protocol paper (Version 1.0, 23rd September 2024) describes 103 104 the methods and analyses planned for this economic evaluation.

105

5

It is made available under a CC-BY 4.0 International license .

106 Methods and analysis:

107

108 Study design

- 109 The NOTACS trial protocol (Trial registration ID: ISRCTN14092678) and statistical analysis plan are
- 110 published elsewhere following the SPIRIT recommendations (Fig 1 & Table S1; S1 Appendix) (17–19). The
- 111 trial examines patient centred outcomes for HFNT versus SOT comparison by using a single-blind strategy
- that assigns eligible patients randomly in a 1:1 allocation ratio, until a sample size of 1280 cases is achieved
- by recruiting participants from 10 sites in the UK, 7 in AUS and 1 in NZ. The trial population includes adult
- 114 patients undergoing elective or urgent first-time or redo cardiac surgery performed on cardiopulmonary
- 115 bypass, having one or more clinical risk factors for PPC. Randomisation is performed after surgery
- initiation and patients are followed up for 90 days after surgery.
- 117 Fig 1. Outlines study components in accordance with SPIRIT guidelines
- 118 (EuroSCORE II: European System for Cardiac Operative Risk Evaluation, ARISCAT risk assessment: Assess
- 119 Respiratory Risk in Surgical Patients in Catalonia, EQ-5D-5L: EuroQol 5-Dimensions 5-Levels, ROX index:
- 120 Ratio of Oxygen Saturation to FiO2 and Respiratory Rate)

121 Intervention and control arms

After cardiac surgery, patients are transferred to intensive care units (ICU). Once a patient fulfils the local hospital criteria for extubation, they are extubated as per the trial extubation protocol (17). Those randomised to the intervention arm receive HFNT for a minimum of 16 hours with up to one hour off treatment allowed for hospital moves or physiotherapy mobilisation. Following the extubation protocol, patients allocated HFNT are started off on 40% fraction of inspired oxygen (FiO2) and a flow of 30 litres per minute (L/min) then up to 50 L/min over 5 to 10 minutes. Patients are monitored and clinically

It is made available under a CC-BY 4.0 International license .

assessed at least every 24 hours to either discontinue, continue, or escalate respiratory support as
 recommended by the trial protocol (17).

130

Patients assigned to control arm follow the exact same pathway except for a difference in the mode of oxygen therapy delivery following extubation. Patients receive SOT via nasal prongs or non-rebreathing masks (not humidified and not heated) as is currently practiced. Patients on SOT are started on 30–40% inspired oxygen at a flow of 2 to 6 L/min, monitored and assessed as recommended (17).

135

136 Within trial economic evaluation

The economic analysis is designed to inform decisions in the UK, AUS, and NZ. Given the difference 137 138 between these health systems, the perspective most relevant to decision-making country will be chosen 139 first for analysis. This includes the National Health Service (NHS) and Personal Social Services (PSS) 140 perspective in the UK, the health care system (Medicare/Australian Government Department of Social 141 Services, including costs accruing both in public and private hospitals) perspective in AUS and the health 142 sector and individual perspective in NZ (20-22). A trial wide pooled cost-effectiveness results, if 143 determined following analyses, will use a health and social care sector perspective. The time horizon for 144 the analysis is 90 days post-surgery.

145

Data collection takes place at five main time points; baseline (surgery admission), randomisation (during or after surgery, prior to extubation), on day of discharge, and on days 30 (+30-day follow-up window) and 90 (+90-day follow-up window) following surgery. The first patient was recruited on 7/10/2020, the last patient recruited on 19/06/2024 and final follow-up is expected to be completed by 16/12/2024. Some data is also collected between time points, for example inpatient location and patient location diary

It is made available under a CC-BY 4.0 International license .

during follow-up. Data collection records patient outcomes, resources and services utilised from both the health/social care sector and patient/family perspective. Data collection tools were designed in the UK following inputs from the trial team, patients, their carers, and members of the public. The tools were adapted for use in AUS with advice from the trial team and patient public representatives and in NZ with advice from the trial team. The data collection tools use country specific questions or response categories where necessary and accounts for good practice and methods guidance (20,23).

157

¹⁵⁸ Costing: identification, measurement, and valuation of resources

a) Identification of resource use

160 Resource use relates to setting up and delivery of HFNT (including the HFNT device, level of use, associated oxygen consumption, training, and maintenance) or SOT (oxygen flow rate, delivery using nasal mask or 161 162 prong) and its consequences i.e. use of hospital, primary, community and social care until 90 days after 163 surgery for both trial arms. Resource use from the individual/family perspective include expenses for 164 medical, non-medical and social care support services, and time spent by patients and caregivers following randomisation. Table 1 provides a summary of all resources and services identified and collected alongside 165 166 the trial. As an incremental approach is used in costing, resources common to both arms and those related 167 to conducting the research are excluded.

168

169

b) Measurement of resource use

Health and social care resources are collected using a variety of patient-specific case report forms (CRFs).
Some are completed by research nurses abstracting data from patient-specific records (e.g. oxygen
therapy, in-patient location, discharge details), some through research nurses interviewing patients faceto-face or using online, telephone or paper questions as preferred (e.g. quality of life, costs over hospital

It is made available under a CC-BY 4.0 International license .

174 stay, service use and expenditure post-surgery). Participant location and medication diary following 175 discharge is the only record directly filled in by the patients. Relevant resources used to provide the service 176 but not limited to specific patients (for example, HFNT training, equipment and maintenance) are 177 measured using research records if available. The source and level of resource use measurements taken 178 are provided in Table 1.

- 179
- 180 Table 1. Identification and measurement of costs

Resource Use	Description of resources used	Unit of measure	Source, level data collected
Health & social	care sector perspective		
HFNT	- HFNT device	- Unit cost	- Published/local sources
intervention	- Training	- Number of	- Project records
setup	- Maintenance	trainings	- Published/local sources
		- Unit cost	
Initial admissio	n		
HFNT	- Amount of oxygen used	- FiO2, flow rate	- CRF, patient specific
	- Consumables	- Duration	- Published manual
SOT	- Amount of oxygen used	- Flow rate	- CRF, patient specific
	- Consumables	- Duration	- Clinical expert opinion
Other	- CPAP, mechanical	- Duration	- CRF, patient specific
ventilation	ventilation, etc.		
support			

Inpatient	- Admission to wards, high	-	Duration	-	CRF, patient specific
admission, by	dependency unit,				
ward	intensive care unit, etc.				
Complications	- Return to operation	-	Frequency	-	CRF, patient specific
after surgery	theatre after initial				
	surgery				
Medications	- All medications during	-	Number of drugs	-	CRF, patient specific
	admission				
Diagnostics	- Blood tests, x-ray, ECG, CT	-	Number of tests	-	CRF, patient specific
	scan, microbiology, etc.				
Health	- Physiotherapy,	-	Number of visits	-	CRF, patient specific
professional	occupational therapy,				
visits	social worker, etc.				
Transport -	- Travel to hospital	-	Number of visits	-	CRF, patient specific
Ambulance					
use					
Discharge to da	y 90 after initial surgery				
Transport -	- Travel to hospital	-	Number of visits	-	CRF, patient specific
Ambulance					
use					
Hospital	- Overnight admission to	-	Number of visits	-	CRF/GP records, patient
admission	hospital, nursing home				specific

Medications	- All medications from	- Number of drugs	- CRF, patient specific
	discharge to day 90		
Diagnostics	- Blood tests, x-ray, etc.	- Number of tests	- CRF, patient specific
Diagnostics			
Day hospital	- Outpatient clinics,	- Number of visits	- CRF, patient specific
services	physiotherapy, accident &		
	emergency, etc.		
GP surgery	- GP surgery to see a	- Number of visits	- CRF, patient specific
services	doctor, nurse, other		
	professionals		
Home visits/	- Home visit from health or	- Number of visits	- CRF, patient specific
telephone	social care professionals		
consultation	- Telephone consultation	- Number of	
		·	
		consultations	
Social support	- Care worker, overnight	- Number of	- CRF, patient specific
services	care, meals on wheels,	contacts	
	ata		
	etc.		
Patient/family	perspective	- -	
Initial admissio	n		
Admission	- Contribution/payment	- Patient reported	- CRF, patient specific
	during initial surgery	cost	
	admission		
	- Travel to and from	- Patient reported	- CRF, patient specific
Transport			

	- Visitor travel			
Miscellaneous	- Food, drink,	- Patient r	eported -	CRF, patient specific
	accommodation exp	ense cost		
Time lost to	- Main activity done b	y - Time lost	: -	CRF, patient specific
illness	patient if not in surg	ery.		
	For example, paid w	ork,		
	unpaid work, caring	etc.		
Accompanying	- Main activity done b	y - Time spe	nt -	CRF, patient specific
person time	accompanying perso	n if		
spent in caring	not caring			
Discharge to da	y 90 after initial surgery			
Admission	- Contribution/payme	nt for - Patient re	eported -	CRF, patient specific
	nursing home, reside	ential cost		
	care, etc.			
Diagnostics	- Contribution/payme	nt for - Patient re	eported -	CRF, patient specific
	blood tests, x-ray, et	c. cost		
Social support	- Contribution/payme	nt for - Patient r	eported -	CRF, patient specific
services	home help, night ca	re, cost		
	meals on wheels, etc	C.		
Medical	- Medical supplies: Fo	r - Patient r	eported -	CRF, patient specific
supplies and	example, prescriptio	ns, cost		
equipment	aspirin, compressior		-	CRF, patient specific
	socks, nebulizer, etc			

It is made available under a CC-BY 4.0 International license .

	- Equipment: For example,	- Patient reported	
	walking aids, special	cost	
	bedding, etc.		
Transport	- Travel to hospital, GP	- Patient reported	- CRF, patient specific
	surgery, etc.	travel time	
Home	- Adaptation made to	- Patient reported	- CRF, patient specific
adaptation	home. For example, ramp,	cost	
	stair-lift, etc.		
Time lost to	- Care arrangements, time	- Patient reported	- CRF, patient specific
illness	off work, etc.	time	
Accompanying	- Main activity done by	- Time spent	- CRF, patient specific
person time	accompanying person if		
spent in caring	not caring		

(HFNT – High Flow Nasal Therapy, FiO2 - fraction of inspired oxygen, CRF – Case Report Form, SOT – Standard Oxygen therapy,
 CPAP - Continuous positive airway pressure, ECG - Electrocardiogram, CT-Scan - Computed Tomography Scan, GP - General
 practitioner)

184

The amount of oxygen used with HFNT and SOT forms a relevant differential resource between the trial arms and hence is costed. As the central oxygen supply is common to both HFNT and SOT, the analysis measures only the variation in amount of oxygen supplied either by HFNT or SOT at a patient-specific level. For SOT, the CRF records oxygen flow rate titration in L/min and duration of use to give total quantity of oxygen used. For HFNT, the CRF records FiO2 and the gas flow rate (L/min). Using an indicative chart, patient-specific data on FiO2 and gas flow rate will be used to determine amount of oxygen used by HFNT (24). Consumables (e.g., oxygen interface, tubing, nasal prong) will be quantified using patient-specific

It is made available under a CC-BY 4.0 International license .

duration of oxygen therapy along with available duration of use guidance given by manufacturer or usingclinical expert opinion (25).

194

The changes to the data collection instruments in AUS and NZ included contextual country-specific questions, responses and wording revisions for resource use data collection. This mainly included replacing country-specific questions on ethnicity, education, healthcare concession and out-of-pocket payments for ambulance travel, health professional visit and telephone consultations in AUS and NZ. Additionally, during the trial, amendments were made to data collection tools to improve data completion. Further details on data collection amendments are available in supplementary Table S2 (S1 Appendix).

202

203 c) Valuation of resource use

All health and social sector resources will be valued using national costs (for example, national cost 204 205 collection in the UK) for the latest available year (26-32). Any unit cost not in the corresponding year will 206 be adjusted using a health- or country-specific inflation index (for example, NHS cost inflation index 207 published in Personal Social Services Research Unit (PSSRU) cost manual) (31,33–36). If national unit costs 208 are unavailable, published literature or local cost sources will be used. Capital costs will be annualised 209 using country-specific discounting recommendations (3.5% UK, 5% AUS, 3.5% NZ) or using the 3.5% UK 210 recommendation for pooled results, further assessed in sensitivity analysis (20,21,37). For example, in 211 base-case, the HFNT device will be annualised using an average lifespan of 5 years, 3.5% discount rate and 212 an annualised maintenance cost using available sources. Patient reported expenses will be used to value 213 patient perspective costs. Time 'spent' by patients and caregivers will be valued using the human capital 214 approach based on gross national average wages (38-40). Unpaid work will be valued using wage earned 215 for similar work on a paid basis or using national average earnings if unavailable.

It is made available under a CC-BY 4.0 International license .

2	1	C
2	Т	0

d) Computation of total costs

218 Total cost will be computed at a patient level by summing the components contributing to the cost of 219 intervention delivery, initial admission and up to 90 days post-surgery relevant to health/social care sector 220 and patient/family perspectives. For example, in base-case, per patient cost of HFNT arm in UK will include 221 NHS/PSS perspective costs for HFNT delivery, initial admission and service utilisation until end of follow-222 up respectively. Total costs will be obtained by multiplying the quantity of resource use by unit cost across 223 each subcomponent and then summing across. Some costs (for example, HFNT device) are expected to 224 be shared between patients. In such cases, annualization, life-span and apportioning rules (for example, 225 number of patients using the device) will be used as appropriate. 226 Identification, measurement, and valuation of health Outcomes: 227 outcomes 228 a) Identification of patient reported outcomes 229 Days alive and at home after surgery (DAH90), a validated patient-reported metric, is the primary outcome 230 231 endpoint for NOTACS trial (41). DAH90/DAH30 define home as a person's usual abode at 90 (and 30) days 232 post-surgery. Escalation of care or time away from usual abode during follow-up period will be counted 233 as a day away from home as per defined protocol. DAH is sensitive to changes in surgical risk and is 234 considered a superior measure of quality of surgery and care than standard complication and mortality 235 rates (42,43). The CRF records changes in the participant's overnight living location throughout follow-up. 236 It includes details on whether stay was planned and if support for daily living activities was needed. The 237 DAH measure will be used in cost-effectiveness analysis (CEA) as it was identified as the most important 238 primary outcome by patient and public representatives during development of the proposal.

239

It is made available under a CC-BY 4.0 International license .

For cost-utility analysis (CUA), a standardised generic health related quality of life measure, the EQ-5D-5L, relevant to the UK, AUS, and NZ is used (20–22,44). The EQ-5D-5L consists of two parts; the first asks respondents to categorise their health today on five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and five response levels (no problems, slight problems, moderate problems, severe problems, unable to) for each dimension, and the second part asks respondents to rate perception of their own overall health today on a scale of 0 (worst) to 100 (best) imaginable health.

246

b) Measurement and valuation of patient reported outcomes.

DAH90 and DAH30 are collected using a mix of CRFs completed by patients and research nurses from date
of index surgery to 90 days after surgery. Patients are given the location diary on discharge and have the
option of completing follow-up questionnaires on paper, online or via telephone. Patients not completing
follow-up CRFs at 30 and 90 days are contacted regularly up to 30+30 and 90+90 days as per trial protocol.
Information may be gathered from the patient's general practitioner (GP) surgery in case of non-response
or to verify patient responses as per consent.

254

255 DAH90/DAH30 valuation accounts for any increase in care level from patient's previous residence. For 256 example, hospital readmission or additional care requirement at 'home' within 90 days of surgery is 257 subtracted from the total number of days at home. Staying away from 'home' for social reasons without any additional care or support is considered as home. The protocol for what counts as days away from 258 259 home is predefined and available in the update of the published statistical analysis plan (submitted and 260 under review). The location is based on where a patient spends the night. Patient records reporting 261 baseline or follow-up abode as 'Other' will be reviewed for whether the 'other' should be classed as 262 'home' and agreed on a case-by-case basis by at least two blinded members. An additional blinded

It is made available under a CC-BY 4.0 International license .

263 member will be consulted if consensus is not reached. If a patient living at home is discharged from the 264 hospital on day 6 after surgery but is subsequently readmitted for 4 days and then returns home until 90 265 days post-surgery, they would be assigned 80 DAH90.

266

267 The base case statistical analysis for the trial follows the approach used by Myles et al., to count days at 268 home i.e. when a patient dies - a DAH value of 0 occurs for the whole period (18,41). For example, if a 269 patient dies while still in the hospital or at home before 90 days, they are assigned 0 DAH90. This means 270 no value is attributed whether a person lives for 1 or 89 days within the study period and no change can 271 be seen if survival changes over time. The trial is not designed to capture change in survival and one 272 reasoning to accept such a scoring is that it takes a more conservative view of benefit. However, for the 273 economic evaluation there are two problems in using this approach. First there is evidence that costs and 274 outcomes can be related and higher costs are particularly related to proximity to death (45–47). Through 275 an increase in outliers, and potential miscasting of the relationship between costs and effects, assigning a 276 zero value to all people dying could significantly bias regression results for cost-effectiveness. Second the 277 cost-utility analysis, part of the suite of tools in economic evaluation used to support NICE's decision-278 making, does account for all days lived. Therefore, the base-case cost-effectiveness analysis will be 279 conducted using all recorded days at home and dubbed 'DAH90(HE)' to represent a difference with 280 calculation of the main trial outcome DAH90, which will be used in sensitivity analysis, to allow comparison 281 with the main trial analysis.

282

Responses recorded on the EQ-5D-5L tool will be converted into a health state utility score using UK, AUS and NZ specific value sets (48–50). As recommended in the UK, the EQ-5D-5L data will be mapped onto the 3L value set (48,51), with QALYs calculated using the area under curve method (52). The study design

286	offers patients a tolerance window of 90 days for 90-day follow-up (and 30+30 days) to complete data
287	collection. Because utility values may be expected to rise over time post-surgery, sensitivity analysis will
288	explore the impact of using linear interpolations to obtain utility values at 90 days (53).
289	
	Analyzia
290 291	Analysis
292 293	a) Handling missing data Before commencing analysis, data quality checks will be conducted and any duplicates, missing or extreme
294	values will be identified and documented. Any missing data will be cross-checked against the CRF and,
295	where necessary, patient records reviewed for procedural error. Clear outliers, such as those exceeding 4
296	standard deviations, will be investigated further and may be excluded or treated as missing values.
297	However, if a series of potential outliers appears within a skewed distribution, they may be retained. In
298	such cases, the data may be transformed (e.g., logarithmic or square root transformation) if necessary
299	and assessed in sensitivity analysis.
300	
301	The pattern and amount of missing data at each time point will be summarised using frequency and
302	percentage plots, with pattern of missingness for resource use and outcomes assessed using Pearson Chi2
303	goodness of fit and Wilcoxon rank-sum tests at each data collection point (54). If data are missing
304	completely at random (MCAR) and the percentage of missing data is below 5%, a complete case analysis
305	(CCA) will be undertaken. This is unlikely to be the case due to the need to aggregate resource use and
306	costs across many variables. Data missing at random (MAR) will be addressed using multiple imputation
307	(MI) methods. Missing cost and outcome data will be estimated using joint chained equations with
308	predictive mean matching, stratified by treatment arm and country. We will explore censoring as a special

It is made available under a CC-BY 4.0 International license .

309 case of missing data, particularly right censoring from loss to follow-up to judge the impact on estimating 310 mean values for costs, DAH90 and QALYs using an inverse probability weighting approach (54). Imputation 311 models will be determined during analysis as it is important that the model includes variables that are 312 good predictors of missing variables. We will consider variables such as age, sex, baseline Barthel and/or EQ-5D-5L scores, baseline health service use, BMI, ethnicity, number of co-morbidities, whether surgery 313 314 is elective, Euro Score II, ASA, and ARISCAT score. The number of imputed datasets required to achieve a 315 stable imputation will be used (55). The distribution of imputed and observed values will be compared 316 across both trial arms. Rubin's rule will be used to generate a complete single data set for analysis, 317 encompassing the variation and uncertainty preserved in the multiple imputed data sets (56). Sensitivity 318 analysis will assess the impact of different missingness assumptions (56). Total costs, DAH90(HE), utility 319 index score at day 90 and total QALYs with CCA, pre-imputed and imputed dataset will be presented for 320 HFNT versus SOT comparison.

321

b) Statistical analysis of differences in resource use, costs, and outcomes for cost-effectiveness and cost-utility analyses

The intention-to-treat principle will be followed for base-case analyses. Resource use, costs and outcomes 324 will be summarised by trial arm; a) at discharge, 30- and 90-days, and b) by country at 90-days using 325 326 descriptive statistics (frequency, mean (standard deviation), median, minimum (including % of zeros), 327 maximum, IQR, 95% confidence interval around the mean, histograms and box plots) along with tests of 328 normality. Significant differences at 5% level, using raw and imputed data, will be tested using two-sample 329 t-tests of equality for normally distributed variables, and the Mann-Whitney-Wilcoxon test and 330 bootstrapped t-tests if skewed. This analysis will be repeated for a complete case analysis if feasible. Changes in the EQ-5D-5L health profile will be summarised using the Paretian Classification of Health 331

It is made available under a CC-BY 4.0 International license .

Change and by reporting the ten most frequently observed health states at baseline and day 90 for both
trial arms (57). A Health Profile Grid will be developed for visual representation (57).

334

335 Regression models will be fitted for mean costs and QALYs, with and without imputed values. Models will 336 include intervention arm and variables to adjust for baseline patient characteristics (age, sex, Barthel, EQ-337 5D score, health service use, BMI, ethnicity, number of co-morbidities and whether surgery is elective, 338 Euro Score II risk score, ASA and ARISCAT score). We will however be unable to control for baseline 339 differences such as patient/family borne costs. We will examine data prior to selecting a regression model but will consider generalised linear or mixed models given their ability to handle large numbers of zeros 340 341 and will test log-link and more flexible forms to examine goodness of fit. We will assess the relationship 342 between baseline covariates for collinearity in the decision for covariate inclusion in the final model. We 343 will also examine the impact of accounting for the correlation between costs and QALYs, by using 344 seemingly unrelated regression analysis with and without correcting for confounding at baseline (58).

345

346 The difference in costs between the trial arms will be divided by the difference in outcomes between the 347 trial arms, to give incremental cost-effectiveness/utility ratios. Incremental cost-utility ratios (ICURs) will 348 be compared with country-specific costs-effectiveness thresholds (CET) used in the UK (£20,000/QALY), 349 AUS (AUS 28,033/QALY) and NZ (NZS 40,000/QALY) (20,45,46). Fully pooled results will be reported in the 350 UK currency (country-specific unit cost applied to resource use followed by summing of all costs to UK currency using purchasing power parity (PPP)) and assessed against the CET value for UK. Country-specific 351 352 incremental net monetary benefit (NMB) statistics, (INMB = incremental benefit * CET – incremental cost) 353 will be presented with 95% CI limits. As no CETs are available for DAH outcome, the incremental cost-354 effectiveness ratios (ICERs) will be used to support wider decision making for any clearly dominant or

355 dominated strategies. We will follow the recommended framework to present cost-effectiveness and 356 cost-utility estimates for this multinational trial (61.62) and present following: a) country-specific ICUR 357 estimates using country-specific data on cost and QALY respectively b) country-specific ICUR estimates 358 using trial-wide resource use valued against country-specific unit costs and trial-wide EQ-5D responses valued against domain level EQ-5D value set for chosen country) and, depending on evidence of 359 360 heterogeneity, c) pooled trial-wide ICUR estimate by applying country-specific unit costs to resource use 361 followed by summing costs to the common UK currency using PPP and summing country-specific QALYs 362 using country-specific value sets into a pooled QALY value. The Likelihood ratio test and range test of 363 qualitative interaction will be used to examine if the direction of cost-effectiveness varies between the 364 countries (63,64). The likelihood ratio and standardised range test statistic will be compared against 365 respective critical values at a significance level of $\alpha = 0.05$ for the three groups to indicate heterogeneity 366 (63,65). We will explore the use of shrinkage estimates as an alternative to trial-wide pooling of cost-367 effectiveness results (66). Table 2 provides the methods and perspective considered in presenting the 368 range of cost-effectiveness results.

369

Table 2. Methods and perspective for presenting the cost-effectiveness results for multinational NOTACStrial.

Analy	Primary	Method	Secondary	Method
sis	(perspective)		(perspective)	
a)	Country specific			
UK	NHS and PSS	Only UK specific data	NHS and PSS	Only UK specific data

			+ Individual (OOPE)	
			+ value of time use	
AUS	Health care system	Only AUS specific data	Health care system	Only AUS specific data
	(includes		(includes public/private)	
	public/private)		+ value of time use	
NZ	Health sector	Only NZ specific data	Health sector	Only NZ specific data
	+ Individual (OOPE)		+ Individual (OOPE)	
			+ value of time use	
b	Country specific - tria	l pooled	I	<u> </u>
UK	NHS and PSS	Resource use – UK, AUS,	NHS and PSS	Resource use – UK, AUS,
		NZ combined	+ Individual (OOPE)	NZ combined
		Unit costs – UK	+ value of time use	Unit costs – UK
		Outcomes – UK, AUS, NZ		Outcomes – UK, AUS, NZ
		combined and valued		combined and valued
		using UK tariff		using UK tariff
AUS	Health care system	Resource use – UK, AUS,	Health care system	Resource use – UK, AUS,
	(includes	NZ combined	(includes public/private)	NZ combined
	public/private)	Unit costs – AUS	+ value of time use	Unit costs – AUS

		Outcomes – UK, AUS, NZ		Outcomes – UK, AUS, NZ
		combined and valued		combined and valued
		using AUS tariff		using AUS tariff
NZ	Health sector	Resource use – UK, AUS,	Health sector	Resource use – UK, AUS,
	+ Individual (OOPE)	NZ combined	+ Individual (OOPE)	NZ combined
		Unit costs – NZ	+ value of time use	Unit costs – NZ
		Outcomes – UK, AUS, NZ		Outcomes – UK, AUS, NZ
		combined and valued		combined and valued
		using NZ tariff		using NZ tariff
c)	Fully pooled			
Trial	Health and social care	Resource use – UK, AUS,	Health and social care	Resource use – UK, AUS,
	sector	NZ	+ Individual (OOPE)	NZ
		Unit costs – UK, AUS, NZ	+ value of time use	Unit costs – UK, AUS, NZ
		Total cost – UK, AUS, NZ		Total cost – UK, AUS, NZ
		combined to UK		combined to UK
		currency using PPP		currency using PPP
		Outcomes – UK, AUS, NZ		Outcomes – UK, AUS, NZ
		tariffs used on		tariffs used on
		respective data for single		respective data for single
		combined QALY measure		combined QALY measure

372	(PPP – F	Purchasing power parity, NHS and PSS – National Health Services and Personal and Social Services, OOPE – Out-of-pocket
373	expendi	iture, AUS – Australia, NZ – New Zealand, UK – United Kingdom)
374		
375		c) Handling uncertainty
376	Param	eter uncertainty will be handled using one-way sensitivity analysis (OWSA) and scenario analysis to
377	assess	the impact of following changes:
378	i)	Costs
379	•	HFNT intervention setup costs, including assumptions about length of life, device use and price.
380	•	Oxygen therapy cost, any variation in oxygen consumption calculation.
381	•	Any significant assumption in measurement or valuation methods for costs, including outliers (for
382		example, methods for follow-up/intravenous medication data collection, discount rate, etc).
383	•	Cost at 30 days.
384	•	Perspective (impact of including patient/family costs)
385		
386	ii)	Outcomes
387	•	DAH90 to assess the impact of assigning a DAH value of zero for those dying between zero to 90
388		days post-surgery.
389	•	Using linear interpolate and 90+90 th day value as a proxy for 90^{th} day utility value in QALY
390		calculation.
391	•	Outcomes at 30 days.
392		
393		

It is made available under a CC-BY 4.0 International license .

394	Sampling uncertainty will be characterised using 95% CI limits for ICUR/ICER values based on non-
395	parametric bootstrapping along with cost-effectiveness plane (CEP) and cost-effectiveness acceptability
396	curves (CEAC) to inform decisions (20).
397	
398	Heterogeneity will be assessed using sub-group analysis to improve robustness of our findings. The
399	potential subgroups to be explored are:
400	Patients requiring escalation of oxygen therapy.
401	Time on treatment (at least 8 or 24 hours)
402	
403	Discussion

404 The NOTACS trial is the first international evidence comparing HFNT versus SOT in adult patients at high

405 risk of developing PPC undergoing cardiac surgery. The trial addresses clinical and economic evidence gaps

- 406 regarding the use of HFNT (10,11). A recent pilot study in this same population subgroup saw a reduction
- 407 in length of hospital stay by 29% and re-admission to ICU dropped from 14% to 2% with HFNT compared
- 408 to SOT (67). HFNT can potentially lead to significant cost-savings and offer good value for investment. The

409 NOTACS trial aims to inform policy recommendations in the UK, AUS, and NZ.

410

411 Strengths

This study has several strengths. First, this is the first study to measure and account for the cost of oxygen therapy with HFNT or SOT following cardiac surgery using prospective, patient-level data. Second, the analysis takes a multinational approach, incorporating methods and guidance relevant to decision-making in three diverse healthcare systems. Our analysis aims at maximising the balance between using available data from the trial with the perspective and methods most relevant to each country. Third, data collection

was influenced by inputs from patients and the public, is country-specific, and records both patient and family costs, and time loss at a patient-level. This yields a potentially valuable source of evidence for broader understanding of the economic implications of HFNT intervention. Fourth, the range of estimates planned for, along with a wide range of sensitivity analyses will give a good indication of the robustness of findings. Finally, the findings can indicate resource utilisation patterns and health benefits in other subpopulations (e.g. following abdominal surgery) where HFNT can be used.

423

424 Limitations

425 There are limitations to the planned analyses. Firstly, in presenting the pooled cost-effectiveness results. 426 the study adopts a health and social care sector perspective. This includes the costs of community-based 427 services and home or continuing care, as recommended in the UK, AUS and NZ (20,68,69). However, this 428 pooled analysis will not include patient perspective costs, which form an important consideration in AUS 429 and NZ. This exclusion may limit the applicability of the pooled trial wide results to these countries. The 430 decision on perspective for pooled analysis was made because the trial was initially designed for, and 431 predominantly recruits from the UK. The analysis however does account for patient perspective costs across all three countries and the cost-utility findings are presented ranging from country-specific to 432 433 pooled trial wide results, presenting relevant economic evidence for decisions. Secondly, the cost-434 effectiveness analysis findings using DAH outcome measure relies on participation diaries completed by 435 patients to record any changes in location. Despite efforts to follow-up with patients' GP practice for 436 incomplete records, there still may be instances where this information is unavailable, potentially 437 influencing the cost-effectiveness findings. Thirdly, the analysis focuses on the cost-effectiveness of HFNT 438 for patients included in controlled trial settings which may differ from the broader population or more 439 real-world clinical settings. Finally, results are limited to 90 days of follow up and cost-effectiveness over 440 a longer period may differ.

It is made available under a CC-BY 4.0 International license .

441

442 Ethics and dissemination:

The study received ethics approval in the United Kingdom from Yorkshire & The Humber- Leeds West 443 Research Ethics Committee, Newcastle upon Tyne, UK on 2nd April 2020 (REC ref: 20/YH/0133). In 444 Australia, the approval was obtained from South Metropolitan Health Service Human Research Ethics 445 Committee, MURDOCH, Western Australia on 3rd September 2021 (ref: RGS0000004935) and 19th May 446 447 2022 (Ref: RGS0000005326), from St John of God Health Care Human Research Ethics Committee (ref: 448 1870) on 13th October 2021, and West Australian Aboriginal Health Ethics Committee (ref: HREC1146) on 449 29th April 2022. In New Zealand, the approval was obtained from Health and Disability Ethics Committees, 450 Wellington, New Zealand on 12 October 2021 (ref: 21/STH/213). Written informed consent will be 451 obtained from all participants. The results will be published in peer reviewed journals and presented at scientific conferences to inform stakeholders. Study newsletters and lay summaries on webpages will be 452 used to disseminate the findings to patients. 453

454

455 Acknowledgements

456 We wish to thank all patients, family members, and staff members from all the participating sites for

457 their involvement in this study.

458

459

460 **References**:

4611.NICOR | Adult Cardiac Surgery (Surgery Audit) [Internet]. [cited 2023 Dec 13]. Available from:462https://www.nicor.org.uk/adult-cardiac-surgery-surgery-audit/

463 464	2.	About The Database ANZSCTS [Internet]. [cited 2023 Dec 13]. Available from: https://anzscts.org/database/about/
465 466 467 468	3.	Ball L, Costantino F, Pelosi P. Postoperative complications of patients undergoing cardiac surgery. Curr Opin Crit Care [Internet]. 2016 Aug 1 [cited 2023 Dec 13];22(4):386–92. Available from: https://journals.lww.com/co- criticalcare/fulltext/2016/08000/postoperative_complications_of_patients_undergoing.18.aspx
469 470 471	4.	Snowdon D, Haines TP, Skinner EH. Preoperative intervention reduces postoperative pulmonary complications but not length of stay in cardiac surgical patients: a systematic review. J Physiother. 2014 Jun 1;60(2):66–77.
472 473 474 475	5.	Westerlind A, Nilsson F, Ricksten SE. The use of continuous positive airway pressure by face mask and thoracic epidural analgesia after lung transplantation. Gothenburg Lung Transplant Group. J Cardiothorac Vasc Anesth [Internet]. 1999 [cited 2022 May 4];13(3):249–52. Available from: https://pubmed.ncbi.nlm.nih.gov/10392672/
476 477 478	6.	Gümüş F, Polat A, Yektaş A, Erentuğ V, Alagöl A. Readmission To Intensive Care Unit After Coronary Bypass Operations in the Short Term. Turk J Anaesthesiol Reanim [Internet]. 2014 [cited 2022 May 4];42(4):162. Available from: /pmc/articles/PMC4894143/
479 480 481	7.	Bardell T, Legare JF, Buth KJ, Hirsch GM, Ali IS. ICU readmission after cardiac surgery. European Journal of Cardio-Thoracic Surgery [Internet]. 2003 Mar 1 [cited 2023 Dec 13];23(3):354–9. Available from: https://dx.doi.org/10.1016/s1010-7940(02)00767-4
482 483 484	8.	Jabbari A, Alijanpour E, Tabasi S. Clinical Usage of High-flow Oxygenation in Postcardiac Surgery Patients. Ann Card Anaesth [Internet]. 2019 Jan 1 [cited 2023 Dec 13];22(1):107. Available from: /pmc/articles/PMC6350429/
485 486	9.	Maggiore SM, Battilana M, Serano L, Petrini F. Ventilatory support after extubation in critically ill patients. Lancet Respir Med. 2018 Dec 1;6(12):948–62.
487 488 489 490 491	10.	Lu Z, Chang W, Meng S, Xue M, Xie J, Xu J, et al. The Effect of High-Flow Nasal Oxygen Therapy on Postoperative Pulmonary Complications and Hospital Length of Stay in Postoperative Patients: A Systematic Review and Meta-Analysis. J Intensive Care Med [Internet]. 2020 Oct 1 [cited 2022 Sep 4];35(10):1129–40. Available from: https://journals.sagepub.com/doi/full/10.1177/0885066618817718
492 493 494	11.	Wu X, Cao W, Zhang B, Wang S. Effect of high-flow nasal cannula oxygen therapy vs conventional oxygen therapy on adult postcardiothoracic operation: A meta-analysis. Medicine [Internet]. 2018 Oct 1 [cited 2022 Sep 4];97(41). Available from: /pmc/articles/PMC6203525/
495 496 497 498	12.	Eaton Turner E, Jenks M. Cost-effectiveness analysis of the use of high-flow oxygen through nasal cannula in intensive care units in NHS England. Expert Rev Pharmacoecon Outcomes Res [Internet]. 2017 Dec 5 [cited 2022 Sep 5];18(3):331–7. Available from: https://europepmc.org/article/med/29187008
499 500	13.	Groessl EJ, Tally SR, Hillery N. Cost-Effectiveness of Humidified High-Flow Therapy (HHFT) for COPD Patients on Long-Term Oxygen Therapy. ClinicoEconomics and Outcomes Research

501 502 503		[Internet]. 2023 Apr 5 [cited 2023 Jun 29];15:239–50. Available from: https://www.dovepress.com/cost-effectiveness-of-humidified-high-flow-therapy-hhft-for-copd- patie-peer-reviewed-fulltext-article-CEOR
504 505 506 507	14.	Sørensen SS, Storgaard LH, Weinreich UM. Cost-Effectiveness of Domiciliary High Flow Nasal Cannula Treatment in COPD Patients with Chronic Respiratory Failure. Clinicoecon Outcomes Res [Internet]. 2021 [cited 2022 Sep 5];13:553–64. Available from: https://pubmed.ncbi.nlm.nih.gov/34168472/
508 509 510 511	15.	Fleeman N, Mahon J, Bates V, Dickson R, Dundar Y, Dwan K, et al. The clinical effectiveness and cost-effectiveness of heated humidified high-flow nasal cannula compared with usual care for preterm infants: systematic review and economic evaluation. Health Technol Assess (Rockv). 2016 Apr 25;20(30):1–68.
512 513 514 515	16.	Buendía JA, Acuña-Cordero R, Rodriguez-Martinez CE. The cost-utility of early use of high-flow nasal cannula in bronchiolitis. Health Econ Rev [Internet]. 2021 Dec 1 [cited 2022 Oct 29];11(1):1–8. Available from: https://healtheconomicsreview.biomedcentral.com/articles/10.1186/s13561-021-00339-7
516 517 518 519 520	17.	Earwaker M, Villar S, Fox-Rushby J, Duckworth M, Dawson S, Steele J, et al. Effect of high-flow nasal therapy on patient-centred outcomes in patients at high risk of postoperative pulmonary complications after cardiac surgery: a study protocol for a multicentre adaptive randomised controlled trial. Trials [Internet]. 2022 Dec 1 [cited 2023 Dec 14];23(1):1–18. Available from: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06180-5
521 522 523 524 525	18.	Dawson SN, Chiu Y Da, Klein AA, Earwaker M, Villar SS. Effect of high-flow nasal therapy on patient-centred outcomes in patients at high risk of postoperative pulmonary complications after cardiac surgery: a statistical analysis plan for NOTACS, a multicentre adaptive randomised controlled trial. Trials [Internet]. 2022 Dec 1 [cited 2023 Dec 14];23(1):1–8. Available from: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06607-z
526 527 528	19.	Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: Defining standard protocol items for clinical trials. Ann Intern Med [Internet]. 2013 Feb 5 [cited 2024 Sep 18];158(3):200–7. Available from: www.annals.org
529	20.	4 Economic evaluation NICE health technology evaluations: the manual Guidance NICE.
530 531 532	21.	PBAC Guidelines 3A.1 Overview and rationale of the economic evaluation [Internet]. [cited 2023 Dec 15]. Available from: https://pbac.pbs.gov.au/section-3a/3a-1-overview-and-rationale-of-economic-evaluation.html
533 534 535	22.	Economic analysis - Pharmac New Zealand Government [Internet]. [cited 2023 Dec 15]. Available from: https://pharmac.govt.nz/medicine-funding-and-supply/the-funding- process/policies-manuals-and-processes/economic-analysis
536 537 538 539	23.	Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report. Value in Health [Internet]. 2015 Mar 1 [cited 2023 Dec 21];18(2):161–72. Available from: http://www.valueinhealthjournal.com/article/S1098301515000169/fulltext

540 541	24.	AIRVO 2 HighFlow Standard Operating Procedure Paediatric Intensive Care Unit (PICU) Royal Hospital for Children Glasgow.
542 543 544	25.	Airvo™ 2 Nasal High Flow/HFNC System [2 - 60 L/min] Fisher & Paykel Healthcare [Internet]. [cited 2023 Dec 15]. Available from: https://www.fphcare.com/en-gb/hospital/adult- respiratory/optiflow/airvo-2-system/
545 546	26.	NHS England » National Cost Collection for the NHS [Internet]. [cited 2022 Oct 3]. Available from: https://www.england.nhs.uk/costing-in-the-nhs/national-cost-collection/
547 548	27.	Pharmaceutical Benefits Scheme (PBS) Home [Internet]. [cited 2024 Jun 28]. Available from: https://www.pbs.gov.au/pbs/home
549 550	28.	National Hospital Cost Data Collection IHACPA [Internet]. [cited 2024 Jun 28]. Available from: https://www.ihacpa.gov.au/health-care/costing/national-hospital-cost-data-collection
551 552 553	29.	Cost Resource Manual - Pharmac Te Pātaka Whaioranga NZ Government [Internet]. [cited 2024 Jun 28]. Available from: https://pharmac.govt.nz/medicine-funding-and-supply/the-funding-process/policies-manuals-and-processes/economic-analysis/cost-resource-manual
554 555 556 557	30.	Average weekly earnings in Great Britain - Office for National Statistics [Internet]. [cited 2024 Jun 28]. Available from: https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemploye etypes/bulletins/averageweeklyearningsingreatbritain/april2024
558 559 560	31.	Unit Costs of Health and Social Care programme (2022 – 2027) The new home for the Unit Costs of Health and Social Care report [Internet]. [cited 2024 Jun 17]. Available from: https://www.pssru.ac.uk/unitcostsreport/
561 562	32.	MBS Online - MBS Online [Internet]. [cited 2024 Aug 8]. Available from: https://www.mbsonline.gov.au/
563 564 565 566	33.	nhs cost inflation index - Google Search [Internet]. [cited 2022 Oct 29]. Available from: https://www.google.com/search?q=nhs+cost+inflation+index&rlz=1C1GCEV_enGB992GB993&oq =NHS+cost+inflation+&aqs=chrome.0.0i512l2j69i57j0i512j0i390.3778j0j7&sourceid=chrome&ie= UTF-8
567 568 569	34.	Appendix A: Use of GDP deflator - NHS Digital [Internet]. [cited 2022 Oct 29]. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/adult-social-care-activity- and-finance-report/2020-21/appendix-a
570 571	35.	Consumers price index (CPI) Stats NZ [Internet]. [cited 2024 Jun 28]. Available from: https://www.stats.govt.nz/indicators/consumers-price-index-cpi/
572 573 574	36.	Consumer Price Index, Australia, March Quarter 2024 Australian Bureau of Statistics [Internet]. [cited 2024 Jun 28]. Available from: https://www.abs.gov.au/statistics/economy/price-indexes- and-inflation/consumer-price-index-australia/latest-release
575 576	37.	8 Discounting - Pharmac New Zealand Government [Internet]. [cited 2023 Nov 24]. Available from: https://pharmac.govt.nz/medicine-funding-and-supply/the-funding-process/policies-

577 578		manuals-and-processes/economic-analysis/prescription-for-pharmacoeconomic-analysis- methods-for-cost-utility-analysis/8-discounting/
579 580	38.	Home - Office for National Statistics [Internet]. [cited 2023 Aug 23]. Available from: https://www.ons.gov.uk/
581 582	39.	Australian Bureau of Statistics [Internet]. [cited 2023 Aug 23]. Available from: https://www.abs.gov.au/
583	40.	Home Stats NZ [Internet]. [cited 2023 Aug 23]. Available from: https://www.stats.govt.nz/
584 585 586 587	41.	Myles PS, Shulman MA, Heritier S, Wallace S, McIlroy DR, McCluskey S, et al. Validation of days at home as an outcome measure after surgery: a prospective cohort study in Australia. BMJ Open [Internet]. 2017 Aug 1 [cited 2023 Jul 1];7(8). Available from: https://pubmed.ncbi.nlm.nih.gov/28821518/
588 589 590 591	42.	Bell M, Eriksson LI, Svensson T, Hallqvist L, Granath F, Reilly J, et al. Days at Home after Surgery: An Integrated and Efficient Outcome Measure for Clinical Trials and Quality Assurance. EClinicalMedicine [Internet]. 2019 May 1 [cited 2023 Jul 1];11:18–26. Available from: https://pubmed.ncbi.nlm.nih.gov/31317130/
592 593	43.	Snowden C, Swart M. Anaesthesia and Perioperative Medicine GIRFT Programme National Specialty Report. 2021;
594 595	44.	FAQs – EQ-5D [Internet]. [cited 2022 Nov 16]. Available from: https://euroqol.org/eq-5d- instruments/eq-5d-5I-about/faqs/
596 597 598	45.	O'Hagan A, Stevens JW. A framework for cost-effectiveness analysis from clinical trial data. Health Econ [Internet]. 2001 Jun 1 [cited 2024 Jul 19];10(4):303–15. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/hec.617
599 600	46.	Howdon D, Rice N. Health care expenditures, age, proximity to death and morbidity: Implications for an ageing population. J Health Econ. 2018 Jan 1;57:60–74.
601 602 603 604	47.	Hazra NC, Rudisill C, Gulliford MC. Determinants of health care costs in the senior elderly: age, comorbidity, impairment, or proximity to death? European Journal of Health Economics [Internet]. 2018 Jul 1 [cited 2024 Jul 19];19(6):831–42. Available from: https://link.springer.com/article/10.1007/s10198-017-0926-2
605 606 607 608	48.	Van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value in Health [Internet]. 2012 Jul 1 [cited 2022 Oct 29];15(5):708–15. Available from: http://www.valueinhealthjournal.com/article/S1098301512000587/fulltext
609 610 611 612	49.	Norman R, Mulhern B, Lancsar E, Lorgelly P, Ratcliffe J, Street D, et al. The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia. Pharmacoeconomics [Internet]. 2023 Apr 1 [cited 2023 Aug 23];41(4):427–38. Available from: https://link.springer.com/article/10.1007/s40273-023-01243-0

613 614	50.	Sullivan T, Hansen P, Ombler F, Derrett S, Devlin N. A new tool for creating personal and social EQ-5D-5L value sets, including valuing 'dead.' Soc Sci Med. 2020 Feb 1;246:112707.
615 616 617 618	51.	Position statement on use of the EQ-5D-5L value set for England (updated October 2019) Technology appraisal guidance NICE guidance Our programmes What we do About NICE. [cited 2022 Oct 29]; Available from: https://www.nice.org.uk/about/what-we-do/our- programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l
619 620 621	52.	Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull [Internet]. 2010 Dec 1 [cited 2024 Jun 18];96(1):5–21. Available from: https://dx.doi.org/10.1093/bmb/ldq033
622 623 624	53.	Linear interpolation - Wikipedia [Internet]. [cited 2024 Jun 18]. Available from: https://en.wikipedia.org/wiki/Linear_interpolation#Linear_interpolation_between_two_known_ points
625 626 627 628	54.	Faria R, Gomes M, Epstein D, White IR. A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials. Pharmacoeconomics [Internet]. 2014 Nov 26 [cited 2023 Jul 2];32(12):1157–70. Available from: https://link.springer.com/article/10.1007/s40273-014-0193-3
629 630 631	55.	White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med [Internet]. 2011 Feb 20 [cited 2023 Jul 2];30(4):377–99. Available from: https://pubmed.ncbi.nlm.nih.gov/21225900/
632 633 634 635	56.	Leurent B, Gomes M, Cro S, Wiles N, Carpenter JR. Reference-based multiple imputation for missing data sensitivity analyses in trial-based cost-effectiveness analysis. Health Econ [Internet]. 2020 Feb 1 [cited 2024 Jul 19];29(2):171–84. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/hec.3963
636 637	57.	Devlin N, Parkin D, Janssen B. Methods for Analysing and Reporting EQ-5D Data. Methods for Analysing and Reporting EQ-5D Data. 2020;
638 639 640	58.	Willan AR, Lin DY, Manca A. Regression methods for cost-effectiveness analysis with censored data. Stat Med [Internet]. 2005 Jan 15 [cited 2023 Jul 3];24(1):131–45. Available from: https://pubmed.ncbi.nlm.nih.gov/15515137/
641 642 643	59.	Edney LC, Haji Ali Afzali H, Cheng TC, Karnon J. Estimating the Reference Incremental Cost- Effectiveness Ratio for the Australian Health System. Pharmacoeconomics [Internet]. 2018 Feb 1 [cited 2023 Aug 23];36(2):239–52. Available from: https://pubmed.ncbi.nlm.nih.gov/29273843/
644 645 646 647	60.	Kvizhinadze G, Wilson N, Nair N, McLeod M, Blakely T. How much might a society spend on life- saving interventions at different ages while remaining cost-effective? A case study in a country with detailed data. Popul Health Metr [Internet]. 2015 Jul 8 [cited 2023 Aug 23];13(1):1–5. Available from: /pmc/articles/PMC4493819/
648 649 650	61.	Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, et al. Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report. Value in Health. 2009 Jun 1;12(4):409–18.

651 652 653 654	62.	Manca A, Willan AR. "Lost in translation": Accounting for between-country differences in the analysis of multinational cost-effectiveness data. Pharmacoeconomics [Internet]. 2006 Nov 25 [cited 2023 Jun 26];24(11):1101–19. Available from: https://link.springer.com/article/10.2165/00019053-200624110-00007
655 656	63.	Gail M, Simon R. Testing for Qualitative Interactions between Treatment Effects and Patient Subsets. Biometrics. 1985 Jun;41(2):361.
657 658	64.	Cook JR, Drummond M, Glick H, Heyse JF. Assessing the appropriateness of combining economic data from multinational clinical trials. Stat Med. 2003 Jun 30;22(12):1955–76.
659 660 661	65.	Piantadosi S, Gail MH. A comparison of the power of two tests for qualitative interactions. Stat Med [Internet]. 1993 Jan 1 [cited 2023 Jul 3];12(13):1239–48. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/sim.4780121305
662 663 664 665 666	66.	Manca A, Lambert PC, Sculpher M, Rice N. Cost-Effectiveness Analysis Using Data from Multinational Trials: The Use of Bivariate Hierarchical Modeling. http://dx.doi.org/101177/0272989X07302132 [Internet]. 2007 Jul 1 [cited 2024 Aug 14];27(4):471–90. Available from: https://journals.sagepub.com/doi/10.1177/0272989X07302132
667 668 669 670	67.	Zochios V, Collier T, Blaudszun G, Butchart A, Earwaker M, Jones N, et al. The effect of high-flow nasal oxygen on hospital length of stay in cardiac surgical patients at high risk for respiratory complications: a randomised controlled trial. Anaesthesia [Internet]. 2018 Dec 1 [cited 2022 Oct 3];73(12):1478–88. Available from: https://pubmed.ncbi.nlm.nih.gov/30019747/
671 672 673 674	68.	Prescription for Pharmacoeconomic Analysis - Pharmac New Zealand Government [Internet]. [cited 2024 May 25]. Available from: https://pharmac.govt.nz/medicine-funding-and-supply/the- funding-process/policies-manuals-and-processes/economic-analysis/prescription-for- pharmacoeconomic-analysis-methods-for-cost-utility-analysis
675 676	69.	PBAC Guidelines Section 3A Cost-effectiveness analysis [Internet]. [cited 2024 May 25]. Available from: https://pbac.pbs.gov.au/section-3a-cost-effectiveness-analysis.html
677		

677

Supporting information 678

- 679 S1 file. S1 Appendix
- 680 S2 file. S2 Appendix

	Study Period					
	Enrolmer	nt	Allocation	Post-all	ocation	Close-out
	Screening	Baseline	Randomization	Discharge	30 Days (+30 days) post-op	90 Days (+90 days) post-op
Timepoint**	Prior to Surgical Admission (or after admission if in-house urgent)	Surgery Admissio n	During or After surgery & prior to extubation	Day of Discharge	30 days (+30 days) post-op	90 days (+90 days) post-op
Enrolment						
Inclusion/Exclusion Criteria	Х					
Informed Consent		х				
Demographics		X				
Past Medical History		Х				
EuroSCORE II & ARISCAT		X				
Preprint (which was not certified by peer revi	/2024.09.29.24314569; this version poste		ne copyright holder for this			
1.1	ade available under a CC-BY 4.0 Internati		play the preprint in perpetuity.			
Initiation of high flow nasal			X			
therapy						
Initiation of standard oxygen therapy			x			
Assessments						
EQ-5D-5L & Barthel Questionnaires		x		x	x	x
Participant & Family Resource Use Questionnaires		x		x	х	х
Adverse & Serious Adverse Events Assessed (from the point of extubation			X			X
Inpatient Medication Log (to start from the point of extubation)			X	X		
Inpatient Location Log (to start from the point of extubation)			X	X		
Inpatient Oxygen Therapy Log (to start from the point of extubation)			X	X		
Participant Location and Medication Diary				X		X
ROX Index			Х	X		
Record of Respiratory Support Escalation			Х	X		
Record of Post-operative Complications			X	Х		
Record of Intensive care Length of stay and Re- admissions				x		
Record of Hospital Discharge Destination				x		
Record of Hospital Length of Stay				X		
- '						

